Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C Hassel, Michael Erdmann, Andrea Forschner, Douglas B Johnson, Renáta Váraljai, Georg Lodde, Jan Malte Placke, Frederik Krefting, Anne Zaremba, Selma Ugurel, Alexander Roesch, Carsten Schulz, Carola Berking, Christoph Pöttgen, Alexander M Menzies, Georgina V Long, Reinhard Dummer, Elisabeth Livingstone, Dirk Schadendorf, Lisa Zimmer
BACKGROUND: Effective treatment options are limited for patients with advanced melanoma who have progressed on immune checkpoint inhibitors (ICI) and targeted therapies (TT). Preclinical models support the combination of ICI with TT; however, clinical trials evaluating the efficacy of triplet combinations in first-line setting showed limited advantage compared to TT only. METHODS: We conducted a retrospective, multicenter study, that included patients with advanced melanoma who were treated with BRAF/MEK inhibitors in combination with an anti-PD-(L)1 antibody (triplet therapy) after failure of at least one anti-PD-(L)1-based therapy and one TT in seven major melanoma centers between February 2016 and July 2022...
March 1, 2024: European Journal of Cancer